Private Equity
Promus Ventures is seeking to raise $75 million for its third fund, according to an SEC filing. The Chicago-based venture firm invests in early-stage deep-tech software/hardware companies.
1 min read · 02 July 2018
1 min read · 02 July 2018
1 min read · 29 June 2018
Industry Ventures has closed its fifth hybrid fund of funds at $335 million. The San Francisco-based venture firm focuses on secondary investments, hybrid fund of funds investments and direct co-investments.
2 min read · 29 June 2018
Inbox Health, a provider of patient communications and payments for medical billers, has raised $2.4 million in funding. Connecticut Innovations led the round with participation from other investors that included I2BF Global Ventures, Launch Capital and Enhanced Capital.
1 min read · 29 June 2018
Shanghai-based I-Mab Biopharma, which focuses on biologics in therapeutic areas of immuno-oncology and immuno-inflammation, has closed $220 million in Series C funding. Hony Capital led the round with participation from Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, EDBI, C-Bridge Capital and Tasly Capital. China Renaissance served as financial adviser on the transaction.
1 min read · 29 June 2018
WelbeHealth, a healthcare company that provides care to medically frail seniors, has raised $15 million in Series B financing. Longitude Capital and Ulysses Diversified Holdings led the round with participation from Town Hall Ventures, F-Prime Capital and .406 Ventures. In conjunction with the financing, Dr. Gregory Grunberg, a managing director of Longitude Capital and Errik Anderson, founder and managing partner of Ulysses, joined WelbeHealth’s board of directors.
1 min read · 29 June 2018
MedCrypt, a medical device cybersecurity technology provider, has secured $1.9 million in seed funding. Eniac Ventures led the round with participation from Sway Ventures, Nex Cubed, Oronoco Investments and Friedman BioVentures.
1 min read · 28 June 2018
Neuronetics, a medical device company, has gone public after pricing its IPO of 5.5 million shares at $17 per share. The stock began trading on the NASDAQ under the ticker symbol "STIM." Piper Jaffray & Co. and William Blair & Company LLC are the lead underwriters. Neuronetics' pre-IPO backers included Ascension Ventures, Accuitive Medical Ventures, GE Ventures, Interwest Partners, New Leaf Venture Partners, Onset Ventures, Polaris Venture Partners and Three Arch Partners.
3 min read · 28 June 2018
Menlo Park, California-based Forty Seven, a clinical stage immuno-oncology company, has debuted its IPO after pricing its over 7 million shares at $16 per share. The stock began trading June 28, 2018 on the NASDAQ under the ticker symbol "FTSV." Morgan Stanley and Credit Suisse are the lead underwriters. Forty Seven's pre-IPO backers include Wellington Management Company LLP, Clarus, Lightspeed Venture Partners, Sutter Hill Ventures and GV.
2 min read · 28 June 2018
